Open Orphan Plc (GB:HVO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Open Orphan Plc has launched its expanded hLAB services, now offering an enhanced suite of virology and immunology laboratory services for drug development, following the recent capacity upgrade at its Canary Wharf facility. The company’s CL-3 lab has received Health & Safety Executive clearance, enabling work with high-risk pathogens, and hLAB has also introduced a biobank approved by the UK Research Ethics Committee. Additionally, hLAB will be present at the World Vaccine Congress in Barcelona, showcasing their expanded capabilities to the vaccine development community.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.